Long Position on GILD @ $71.00 on 2/28/2020 (Rumor)

Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally.

The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections.

In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others.

The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. 

Shares have formed a bullish "cup and handle" on the market rumor that the company may be working on a Coronavirus vaccine. Shares pulled back yesterday after Bloomberg reported that Gilead Sciences (GILD) has approached Forty Seven (FTSV) with a takeover offer, and that the companies have also discussed other options, including a partnership. The report also added that Forty Seven has "received interest from other potential suitors as well," citing their source. 

Last Trade: $71.00

Trading Range: $60.89 - $78.88

Stop Loss: $68.50

Target Price: $78.00

Updates

3/6/2020 2:36:54 PM

GILD closed at $79.10

Position closed on 3/6/2020 at price of $79.10 with a 11.41% gain in 7 days.

Back to Portfolio